Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RSV preF Protein
- Development stage
- Discontinued
- Lead developer
- Johnson & Johnson
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
RSV preF Protein is a vaccine component developed by Janssen Vaccines & Prevention B.V. It is designed to target the pre-fusion form of the Respiratory Syncytial Virus (RSV) F protein to elicit an immune response. The drug is being investigated for safety and immunogenicity in adults aged 60 years and older as a potential vaccine against RSV. It is administered via intramuscular injection, either alone or in combination with an Ad26.RSV.preF viral vector component.
02
Targets
RSV preF (Respiratory syncytial virus prefusion F glycoprotein)
Beyond the preview
Go deeper on RSV preF Protein.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RSV preF Protein.